APA (7th ed.) Citation

Perez-Garcia, G., Bicak, M., Haure-Mirande, J., Perez, G. M., Otero-Pagan, A., Gama Sosa, M. A., . . . Elder, G. A. (2023). BCI-838, an orally active mGluR2/3 receptor antagonist pro-drug, rescues learning behavior deficits in the PS19 MAPTP301S mouse model of tauopathy. Neuroscience Letters, 797, N.PAG. https://doi.org/10.1016/j.neulet.2023.137080

Chicago Style (17th ed.) Citation

Perez-Garcia, Georgina, et al. "BCI-838, an Orally Active MGluR2/3 Receptor Antagonist Pro-drug, Rescues Learning Behavior Deficits in the PS19 MAPTP301S Mouse Model of Tauopathy." Neuroscience Letters 797 (2023): N.PAG. https://doi.org/10.1016/j.neulet.2023.137080.

MLA (9th ed.) Citation

Perez-Garcia, Georgina, et al. "BCI-838, an Orally Active MGluR2/3 Receptor Antagonist Pro-drug, Rescues Learning Behavior Deficits in the PS19 MAPTP301S Mouse Model of Tauopathy." Neuroscience Letters, vol. 797, 2023, p. N.PAG, https://doi.org/10.1016/j.neulet.2023.137080.